
Aldeyra Gets FDA SPA Agreement for ADX-2191 in Eye Cancer Treatment
Aldeyra Gets FDA SPA Agreement for ADX-2191 in Eye Cancer Treatment Aldeyra Therapeutics, Inc. announced it has received a Special Protocol Assessment (SPA) Agreement Letter from the U.S. Food and Drug Administration (FDA) for its investigational drug, ADX-2191 (methotrexate injection,…